

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of identifying an agent that binds to CCX-CKR2 on a cell, the method comprising,
contacting a plurality of agents and a CCX-CKR2 ligand to a CCX-CKR2 polypeptide comprising an extracellular domain at least 95% identical to an extracellular domain of SEQ ID NO:2, or a SDF1 or I-TAC-binding fragment thereof, wherein the CCX-CKR2 ligand is SDF1 or I-TAC; and
selecting an agent that competes with I-TAC or SDF1 for binding to the CCX-CKR2 polypeptide or fragment thereof, thereby identifying an agent that binds to CCX-CKR2 on a cell.
2. (Original) The method of claim 1, wherein the cell is a cancer cell.
3. (Original) The method of claim 1, further comprising testing the selected agent for the ability to bind to, or inhibit growth of, a cell.
4. (Original) The method of claim 3, wherein the cell is a cancer cell.
5. (Original) The method of claim 1, further comprising testing the selected agent for the ability to alter kidney function.
6. (Original) The method of claim 1, further comprising testing the selected agent for the ability to alter brain or neuronal function.
5. (Original) The method of claim 1, further comprising testing the selected agent for the ability to change cell adhesion to endothelial cells.

6/8. (Original) The method of claim 1, wherein the agent is less than 1,500 daltons.

7/9. (Original) The method of claim 1, wherein the agent is an antibody.

8/10. (Original) The method of claim 1, wherein the CCX-CKR2 polypeptide comprises the sequence displayed in SEQ ID NO:2.

11-27. (Canceled)

16/28. (Currently amended) A method comprising contacting a cell with an agent that specifically binds to SEQ ID NO:2, wherein the agent competes with SDF-1 or and I-TAC for binding to a CCX-CKR2 polypeptide, and wherein the cell expresses a CCX-CKR2 polypeptide, comprising an extracellular domain at least 95% identical to an extracellular domain of SEQ ID NO:2.

11/29. (Original) The method of claim 28, wherein the agent is less than 1,500 daltons.

12/30. (Original) The method of claim 28, wherein the agent is an antibody.

13/31. (Original) The method of claim 28, wherein the CCX-CKR2 polypeptide is as displayed in SEQ ID NO:2.

14/32. (Original) The method of claim 28, wherein the agent is identified by a method comprising

contacting a plurality of agents to a CCX-CKR2 polypeptide comprising an extracellular domain at least 95% identical to an extracellular domain of SEQ ID NO:2, or a SDF1 or I-TAC-binding fragment thereof; and

selecting an agent that competes with I-TAC or SDF-1 for binding to the CCX-CKR2 polypeptide or fragment thereof, thereby identifying an agent that binds to a cancer cell.

33-38. (Canceled)

Appl. No. 10/698,541
Amdt. dated October 23, 2006
Reply to Office Action of June 22, 2006

PATENT

⁹ 39. (New) The method of claim 2, wherein the CCX-CKR2 ligand is detectably-labeled and the selecting step comprises measuring the amount of labeled CCX-CKR2 ligand bound to the polypeptide in the presence of at least one of the plurality of agents.